Table 3.
ILS group | Metformin group | Placebo group | |
---|---|---|---|
DPP (2·8 years) | 4·8 (4·1–5·7) | 7·8 (6·8–8·8) | 11·0 (9·8–12·3) |
End of masked treatment (3·2 years) | 5·0 (4·3–5·8) | 7·7 (6·8–8·8) | 10·8 (9·7–12·0) |
Bridge period | 5·5 (4·1–7·5) | 10·6 (8·4–13·2) | 7·8 (5·9–10·3) |
DPPOS (n=2766) | 5·9 (5·1–6·8) | 4·9 (4·2–5·7) | 5·6 (4·8–6·5) |
Combined incidence | 5·3 (4·8–5·8) | 6·4 (5·9–7·1) | 7·8 (7·2–8·6) |
Data are incidence rates (95% CI). The bridge period was Aug 1, 2001, to Aug 31, 2002.
ILS=intensive lifestyle intervention. DPP=Diabetes Prevention Program.